Intranasal interferon (rIFN-αA, Ro 22-8181) for contact prophylaxis against common cold: A randomized, double-blind and placebo-controlled field study

Herzog, Christian; Berger, Rosmarie; Fernex, M; Friesecke, Karen; Havas, L; Just, M; Dubach, U. C.

doi:10.1016/0166-3542(86)90011-2

Cited by 29 publications

(23 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Today, IFN-␣ is established as an essential component of hepatitis B and C treatment regimens (9,17,31). Even though clinical studies demonstrated that intranansal IFN-␣ treatment can also prevent rhinovirus infection and spread (6,14,15), side effects such as irritation of the nasal mucosa and occasional nose bleeding after long-time and repeated administration prevented further in-depth evaluation of the potential therapeutic use of IFN-␣ to combat respiratory diseases such as influenza. The current interest in drugs against influenza is fueled by the threat that circulating avian H5N1 viruses or another subtype may adapt to humans and cause a devastating pandemic.…”

Section: Discussionmentioning

confidence: 99%

“…The exploration of the therapeutic potential of type I IFN began soon after its potent antiviral activity had been discovered (3,15,34,44). Today, IFN-␣ is established as an essential component of hepatitis B and C treatment regimens (9,17,31).…”

Section: Discussionmentioning

confidence: 99%

“…The human MxA protein also inhibits the replication of influenza viruses (30,53). In spite of promising initial clinical studies with IFN-␣ for the treatment of respiratory diseases, side effects such as irritation of the nasal mucosa and occasional nose bleeding have prevented the in-depth evaluation of IFN-␣ as a treatment for these diseases (6,15,19,25). If intranasally applied IFN were effective against influenza A viruses, the benefit would in many cases outweigh the reported mild side effects of the treatment.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Intranasal Administration of Alpha Interferon Reduces Seasonal Influenza A Virus Morbidity in Ferrets

Kugel

Kochs

Obojes

et al. 2009

J Virol

100

View full text Add to dashboard Cite

The type I interferon (IFN) response represents one of the first lines of defense against influenza virus infections. In this study, we assessed the protective potential of exogenous IFN-␣ against seasonal and highly pathogenic influenza viruses in ferrets. Intranasal treatment with IFN-␣ several hours before infection with the H1N1 influenza A virus strain A/USSR/90/77 reduced viral titers in nasal washes at least 100-fold compared to mock-treated controls. IFN-treated animals developed only mild and transient respiratory symptoms, and the characteristic fever peak seen in mock-treated ferrets 2 days after infection was not observed. Repeated application of IFN-␣ substantially increased the protective effect of the cytokine treatment. IFN-␣ did not increase survival after infection with the highly pathogenic H5N1 avian influenza A virus strain A/Vietnam/ 1203/2004. However, viral titers in nasal washes were significantly reduced at days 1 and 3 postinfection. Our study shows that intranasal application of IFN-␣ can protect ferrets from seasonal influenza viruses, which replicate mainly in the upper respiratory tract, but not from highly pathogenic influenza viruses, which also disseminate to the lung. Based on these results, a more intensive evaluation of IFN-␣ as an emergency drug against pandemic influenza A is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Intranasal Administration of Alpha Interferon Reduces Seasonal Influenza A Virus Morbidity in Ferrets

Kugel

Kochs

Obojes

et al. 2009

J Virol

100

View full text Add to dashboard Cite

show abstract

“…Interferon, for example has demonstrated varying degrees of prophylactic efficacy. [20][21][22]24,26 Success with such agents has proven to be elusive to date, 8,[19][20][21][22][23][24][25][26][27][28] as most treatments either have had limited efficacy or have had side-effects, such as nasal irritation, that are more severe than the symptoms of the cold. Very few agents have been found to have any effect once the symptoms have developed, i.e.…”

Section: Discussionmentioning

confidence: 99%

“…The literature on the common cold contains many studies on prophylactic use of such agents as interferons [19][20][21][22][23][24][25][26] and synthetic drugs 8,27,28 in attempts to prevent colds or shorten their duration. Interferon, for example has demonstrated varying degrees of prophylactic efficacy.…”

Section: Discussionmentioning

confidence: 99%

Zinc Gluconate and the Common Cold: A Controlled Clinical Study

et al. 1992

View full text Add to dashboard Cite

A report in 1984 on the success of zinc gluconate against common cold symptoms could not be confirmed in three subsequent studies, which are now known to have used formulations that inactivated zinc. A non-chelating formulation including glycine, which releases 93% of contained zinc into saliva, was tested in a randomized, placebo-controlled, double-blind trial in 73 young adults. Efficacy was recorded in symptom diaries using a symptom severity rating. Patients' symptoms first appeared 1.34 days prior to entry to the study in both groups. Disappearance of symptoms occurred after an additional 4.9 days for zinc-treated patients versus 6.1 days for placebo-treated patients. A difference was noted in the efficacy of treatment if it was started 1 day after symptom onset: cold duration was an additional 4.3 days in zinc-treated patients compared with 9.2 days for placebo-treated patients. Cough, nasal drainage and congestion were the symptoms most affected, and only mild side-effects were noted.

show abstract

Antivirals for the common cold

Jefferson

Tyrrell²

2001

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

There are no licensed effective antivirals for the common cold. Because prolonged intranasal administration causes a clinical picture which is not distinguishable from the common cold, interferons have no place in everyday use. Further assessment of the effects of dipyridamole, palmitate, ICI 130, 685, Impulsin and Pleconaril in preventing the common cold should be carried out. Given the multi-agent nature of the causes of the common cold, future research efforts should focus on non virus-specific compounds.

show abstract

Intranasal interferon (rIFN-αA, Ro 22-8181) for contact prophylaxis against common cold: A randomized, double-blind and placebo-controlled field study

Cited by 29 publications

References 10 publications

Intranasal Administration of Alpha Interferon Reduces Seasonal Influenza A Virus Morbidity in Ferrets

Intranasal Administration of Alpha Interferon Reduces Seasonal Influenza A Virus Morbidity in Ferrets

Zinc Gluconate and the Common Cold: A Controlled Clinical Study

Antivirals for the common cold

Contact Info

Product

Resources

About